NASDAQ:SRPT Sarepta Therapeutics Q2 2026 Earnings Report $15.43 -0.46 (-2.89%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$15.46 +0.03 (+0.16%) As of 08:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sarepta Therapeutics EPS ResultsActual EPSN/AConsensus EPS $0.49Beat/MissN/AOne Year Ago EPSN/ASarepta Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$381.98 millionBeat/MissN/AYoY Revenue GrowthN/ASarepta Therapeutics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Sarepta Therapeutics Earnings HeadlinesMorgan Stanley views Sarepta CEO transition as a 'positive' – so, why is it cautious on SRPT stock in the near term?July 28 at 7:30 AM | msn.comSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerJuly 27 at 10:11 AM | finance.yahoo.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.July 29 at 1:00 AM | Chaikin Analytics (Ad)Sarepta Therapeutics Appoints Michael Severino as CEOJuly 27 at 9:30 AM | tipranks.comSarepta names former Abbvie president as CEO as Ingram retiresJuly 27 at 9:19 AM | reuters.comSarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive OfficerJuly 27 at 9:00 AM | businesswire.comSee More Sarepta Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sarepta Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sarepta Therapeutics and other key companies, straight to your email. Email Address About Sarepta TherapeuticsSarepta Therapeutics (NASDAQ:SRPT) is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities. Sarepta’s commercial products include several exon-skipping therapies approved by the U.S. Food and Drug Administration for specific DMD mutations. Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen) use chemically modified oligonucleotides to induce exon skipping and restore production of functional dystrophin protein. In addition, Elevidys (delandistrogene moxeparvovec) is an adeno-associated virus (AAV)-based gene therapy designed to deliver a shortened dystrophin gene to muscle tissue, representing one of the first approved gene therapies for DMD. Founded in the late 1980s under the name AVI BioPharma and rebranded as Sarepta Therapeutics in 2012, the company initially explored antiviral technologies before pivoting to neuromuscular disease in 2010. Sarepta now maintains commercial operations across North America and has established collaborations in Europe and Asia to support clinical trials and regulatory filings. The company continues to expand its pipeline, exploring next-generation gene editing, microdystrophin constructs and treatments for other genetic muscle disorders such as limb-girdle muscular dystrophy. Leadership at Sarepta is spearheaded by President and Chief Executive Officer Douglas Ingram, who joined the company in 2018 and assumed the CEO role in 2021. Under his guidance, Sarepta has grown from a single-product organization into a multi-asset innovator with a broad platform in precision genetic medicine. The company’s executive team combines expertise in neurology, genetic engineering and regulatory affairs to advance therapies from early-stage research through global commercialization.View Sarepta Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
